Princess Margaret Hospital, University Health Network
Toronto, Ontario, M5G 2M9, Canada
NCT Number: NCT03390569
Patients with newly-diagnosed GBM will be given personalized exercise regimes during concurrent chemo-radiation and up to 3 months later. Study aims are to investigate the feasibility and preliminary efficacy of the exercise program on progression free survival. Secondary outcomes of interest include cognition, fatigue, and quality of life.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Toronto, Ontario, M5G 2M9, Canada
Background: Glioblastoma (GBM) is the most common malignant glioma in adults, with a very poor prognosis, limited new treatment options, and neurological sequelae, including physical and cognitive decline that adversely affect quality of life (QOL). Physical activity may be an intervention that attenuates the cognitive and physical decline associated with GBM. However, few studies examine physical activity in brain tumor patients, perhaps due to challenges in trial design, measuring outcomes, and complexity of care. Aims of this work are to develop and implement an individualized exercise intervention for GBM patients to support functional independence, and to delay tumor progression and cognitive decline. Methods: GBM patients scheduled to be treated with concurrent radiation and chemotherapy will be recruited from the neuro-oncology clinic at the Princess Margaret Cancer Centre. Participants will receive an individualized, home-based exercise program that includes aerobic and resistance training, tailored to prior level of fitness, current physical status, and individual interests. They will undergo 1-hr standardized, validated assessments of physical and neurocognitive functions, mood, fatigue, and QOL, prior to radiation, and then 3, 6, 12, and 18 months later. Significance: Identifying interventions that preserve or improve mobility and cognitive function will enhance QOL and may lengthen progression-free survival in brain tumor patients. Moreover, finding ways to help patients maintain self-care will lessen the strain on the health care system (e.g., fewer hospitalizations, delayed utilization of palliative care hospice).
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The patients meet with a registered physiotherapist and receive individualized exercise programs starting the second week of treatment, and continuing up to 3 months later.
Other names: Fitness, Physiotherapy
Time frame: 6 months
Time to tumor progression, based on Response Assessment in Neuro-Oncology (RANO) criteria
Time frame: 3 months, 6 months, 12 months, 18 months post-treatment
Tests will be scored according to published criteria, converted to z-scores based on population norms, and averaged to create an overall cognitive function score. COgnitive decline will be defined as declined scores at a given time point (preservation of cognitive functions will be defined as stable or improved scores at a given time point).
Time frame: 3 months, 6 months, 12 months, 18 months post-treatment
as measured by a validated questionnaire
Time frame: Up to 18 months post-treatment
rate of overall survival
Time frame: 3, 6, 12 and 18 months post-treatment
as measured by a standardized questionnaire
Time frame: 3, 6, 12 and 18 months post-treatment
as measured by a validated questionnaire
Time frame: 3, 6, 12 and 18 months post-treatment
as measured by a validated questionnaire
Time frame: 3, 6, 12 and 18 months post-treatment
as measured by a validated questionnaire
Time frame: 3, 6, 12 and 18 months post-treatment
as measured by a validated questionnaire
Time frame: 3, 6, 12 and 18 months post-treatment
strength, balance, cardiovascular endurance
University Health Network, Toronto
Other
Does Exercise Improve Progression-free Survival in Glioblastoma? A Prospective Single Arm Intervention Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04817254
Astrocytoma, Brain Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT04446416
Astrocytoma, Brain Diseases
Taoyuan City, Taiwan
View Trial DetailsNCT07499141
Astrocytoma, Brain Diseases
Alessandria, Italy
View Trial DetailsNCT06439420
Astrocytoma, Brain Diseases
Richmond, Virginia, United States
View Trial Details